Haematologica HAEMATOL/2019/235598 Version 3

Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors

Tomotaka Suzuki, Suguru Fukuhara, Junko Nomoto, Satoshi Yamashita, Akiko (Miyagi) Maeshima, Yuta Ito, Shunsuke Hatta, Sayako Yuda, Shinichi Makita, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Hirokazu Taniguchi, Toshikazu Ushijima, Koji Izutsu, Kensei Tobinai, and Yukio Kobayashi

Disclosures: Dr. Tatsuya Suzuki reports personal fees from Chugai Pharmaceutical, outside the submitted work; . Dr. Maruyama, M.D. / Ph.D. reports grants and personal fees from Chugai, grants and personal fees from Takeda, during the conduct of the study; grants from Sanofi, grants and personal fees from Janssen, grants and personal fees from Eisai, grants and personal fees from Celegene, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Ono, grants and personal fees from Mundipharma, grants and personal fees from MSD, grants and personal fees from Zenyaku, personal fees from Sumitomo, personal fees from Asahi Kasei, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Daiichi Sankyo, grants and personal fees from AstraZeneca, personal fees from Linical, personal fees from Pharma International, personal fees from Fujimoto, grants from Abbvie, grants from Astellas, grants from Amgen Astellas Biopharma, grants from Otsuka, grants from Novartis, grants from Pfizer, grants from Solasia, grants from Bayer, grants from Symbio, grants from CMIC, grants from Quintiles, grants from IQvia, outside the submitted work; . Dr. Izutsu reports grants and personal fees from Eisai, grants and personal fees from MSD, grants and personal fees from Takeda, grants and personal fees from Janssen, personal fees from Bristol Myers Squib, personal fees from Dainihon Sumitomo, grants and personal fees from Mundipharma, personal fees from Nihon Mediphysics, grants and personal fees from Chugai, grants and personal fees from Astra Zeneca, grants and personal fees from Abbvie, grants and personal fees from Bayer, grants and personal fees from Ono, grants from Gilead, grants from Zenyaku, grants and personal fees from Celgene, grants from Solasia, grants from Symbio, grants from Astellas, grants from Astellas Amgen, grants from Bayer, from Daiichi Sankyo, personal fees from Kyowa Hakko Kirin, outside the submitted work; . Dr. Tobinai reports personal fees from Zenyaku Kogyo, grants and personal fees from Eisai, grants and personal fees from Takeda, grants and personal fees from Mundipharma, personal fees from HUYA Bioscience International, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Celgene, grants and personal fees from Chugai Pharma, grants and personal fees from Ono Pharmaceutical, personal fees from Yakult, personal fees from Daiichi Sankyo, personal fees from Bristol-Myers Squibb, personal fees from Meiji Seika Kaisha, personal fees from Solasia Pharma, personal fees from Verastem, grants from Janssen, grants from Abbvie, outside the submitted work; . Dr. Kobayashi reports grants, personal fees and other from Pfizer, personal fees from Astellas, personal fees from Symbio, outside the submitted work;

Haematologica HAEMATOL/2019/235598 Version 3

Contributions: ToS collected the data. ToS, SF, YI, SH, SY, SM, WM, TaS, DM, KI, KT, and YK provided the cases. AM and HT performed the immunohistological evaluations. ToS, JN, SY, and TU performed the genetic analyses and interpreted the data. ToS and SF wrote the preliminary draft of the manuscript. All authors revised the subsequent drafts and approved the final version for submission.